Trial Profile

ATTAC-MCC: Phase I/II Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity MCPyV-specific TCRs Combined With Avelumab and Class I MHC-upregulation in Patients With Metastatic MCC Refractory to PD-1 Axis Blockade

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Interferon gamma-1b (Primary) ; Merkel cell polyomavirus specific TCR redirected T cell therapy bluebird bio/Fred Hutchinson Cancer Research Center (Primary) ; Pembrolizumab (Primary)
Indications Merkel cell carcinoma
Focus Adverse reactions; Proof of concept; Therapeutic Use

29 Oct 2024 Status changed from active, no longer recruiting to discontinued.
22 Mar 2024 Planned End Date changed from 15 Apr 2025 to 10 Jan 2025.
22 Mar 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com